Summary

In North America the aging population has contributed to an increased prevalence of diabetes, as the risk of developing diabetes tends to rise with age. This demographic trend has driven the demand for blood glucose monitoring devices in the region. The number of people in North America over the age of 65 is increasing, and this age group is at higher risk for developing diabetes. Obesity is a major risk factor for developing type 2 diabetes, and the prevalence of obesity is also increasing in North America. Physical activity can help to prevent type 2 diabetes, and the amount of physical activity that people are getting is declining in North America. People who live in urban areas are more likely to develop type 2 diabetes, possibly due to factors such as a lack of access to fresh fruits and vegetables, and limited opportunities for physical activity. The high prevalence of diabetes in North America is a significant public health concern, as it can lead to a number of serious complications, including heart disease, stroke, blindness, kidney failure, and nerve damage. It is important to manage diabetes effectively to prevent these complications. Lifestyle factors, such as sedentary behavior and poor dietary habits, contribute to the rising incidence of diabetes in North America. As these factors persist, the demand for effective blood glucose monitoring tools continues to grow. The availability of insurance coverage for blood glucose monitoring devices in North America enhances affordability and accessibility for patients. Insurance policies that cover the costs of these devices can significantly influence their adoption rates. The design and features of blood glucose monitoring devices that prioritize patient convenience and seamlessly integrate into daily life contribute to their widespread use. Compact, portable devices with user-friendly interfaces enhance user satisfaction and compliance.

According to the research report, "North America Blood Glucose Monitoring Devices Market Outlook, 2028," published by Bonafide Research, the North America Blood Glucose Monitoring Devices market is anticipated to grow at a 7% CAGR by 2023–28. Blood glucose monitors are increasingly being integrated with digital health platforms and mobile applications. This integration enables users to track and analyze their glucose levels on smartphones, share data with healthcare providers, and receive personalized insights. The development of smart insulin pens and advanced insulin delivery systems is a notable trend. These devices often integrate with digital platforms, offering features such as dose reminders, insulin tracking, and connectivity to healthcare providers. Non-invasive or minimally invasive glucose monitoring technologies have been a focus of research and development. The trend is towards devices that can measure glucose levels without the need for fingerstick testing, providing a more comfortable experience for individuals with diabetes. The incorporation of artificial intelligence and predictive analytics into blood glucose monitors is becoming more prevalent. These technologies analyze historical data to predict future glucose levels, providing users with proactive insights and personalized recommendations. There is an increasing emphasis on designing blood glucose monitors that are user-friendly, compact, and easy to use. User-centric design features, such as touchscreens, intuitive interfaces, and ergonomic form factors, enhance the overall user experience. The integration of blood glucose monitoring features into wearable devices, such as smartwatches, is a growing trend. Wearables provide a convenient way for users to monitor their glucose levels continuously, and they often come with additional health and fitness tracking capabilities. The adoption of 5G technology is impacting the connectivity and data transfer capabilities of blood glucose monitors. Faster and more reliable communication can enhance remote monitoring and the seamless transfer of data between devices and healthcare providers.

Based on country the market is divided into United States, Canada and Mexico. Among them United States is leading the market. The United States has a large and growing population, and the prevalence of diabetes is significant. According to the Centers for Disease Control and Prevention (CDC), more than 34 million people in the United States have diabetes, with around 1.5 million new cases diagnosed every year. The high incidence of diabetes drives the demand for blood glucose monitoring devices. According to the national center for health statistics, more than 30 % of adults aged 18 and over in the United States will be obese in 2021. In the United States, there are several innovations in diabetes management platforms by startups like Glooko, OneDrop, Verily, Vascate, Insulet, Noom, Bigfoot Biomedical, Virta Health, Diabeloop and Orgenesis which have lanched in the market. Furthermore, Mexico has a high prevalence of diabetes, making it a significant driver for the Blood Glucose Monitoring Devices Market. The International Diabetes Federation has reported a notable increase in diabetes cases in Mexico. The demand for monitoring devices is directly linked to the increasing number of individuals diagnosed with diabetes. Furthermore, Mexico has been working to improve its healthcare infrastructure. Enhanced healthcare facilities, better access to healthcare services, and an increasing number of trained healthcare professionals contribute to the growth of the market, as these factors support the adoption of blood glucose monitoring devices.

Based on product market is bifurcated into Self-monitoring Devices and Continuous Blood Glucose Monitoring Devices. The dominance of the self-monitoring devices segment in the North America blood glucose monitoring devices market. SMBG devices are widely available and affordable, making them accessible to individuals with diabetes across various socioeconomic backgrounds. This accessibility ensures that individuals with diabetes have the tools they need to monitor their blood sugar levels effectively. SMBG devices are becoming increasingly integrated with healthcare systems, allowing individuals with diabetes to share their blood sugar readings with their healthcare providers. This integration facilitates better diabetes management and timely interventions when needed. SMBG devices are providing individuals with diabetes with personalized data insights, enabling them to make informed decisions about their lifestyle choices and medication regimens. This personalized data empowers individuals with diabetes to take charge of their health and optimize their diabetes management. SMBG devices are empowering individuals with diabetes to take ownership of their health and actively manage their diabetes. By providing real-time blood sugar readings and insights, SMBG devices promote self-management and adherence to treatment plans. SMBG devices are facilitating early detection of diabetes complications, such as hypoglycemia and hyperglycemia. By providing timely alerts and notifications, SMBG devices allow individuals with diabetes to take prompt action to prevent or manage these complications. Regular blood sugar monitoring with SMBG devices plays a crucial role in preventing long-term health issues associated with diabetes, such as heart disease, stroke, kidney damage, and nerve damage.

The diagnostic centers segment is expected to experience the highest CAGR during the forecast period in the North America blood glucose monitoring devices market. The prevalence of diabetes in North America is on the rise, and this is leading to an increased demand for diagnostic services, including blood glucose monitoring. Diagnostic centers are well-equipped to provide these services, and they are often staffed by qualified healthcare professionals who can interpret blood glucose readings and provide personalized advice. Diagnostic centers are adopting advanced technologies, such as continuous glucose monitoring (CGM) devices, to provide more accurate and real-time blood glucose monitoring. This is making diagnostic centers a more attractive option for people with diabetes who require more intensive blood glucose monitoring. Governments in North America are implementing initiatives to promote the use of diagnostic centers for blood glucose monitoring. These initiatives are helping to raise awareness of the benefits of diagnostic centers and are making them more affordable for people with diabetes. Definitive Healthcare, a healthcare data company, tracks over 18,800 imaging centers in the United States. This number includes imaging centers that perform a variety of imaging modalities, such as X-rays, CT scans, and MRIs.

Companies Covered in this report:

F. Hoffmann-La Roche AG, Abbott Laboratories, Nipro Corporation, B. Braun Melsungen AG, Medtronic plc, DexCom, Inc, Ypsomed AG, LifeScan, Inc, Bionime Corporation, Sanofi S.A., Senseonics Inc, DarioHealth.

Considered in this report

• Geography: North America
• Historic year: 2017
• Base year: 2022
• Estimated year: 2023
• Forecast year: 2028

Aspects covered in this report

• North America Blood Glucose Monitoring Devices market Outlook with its value and forecast along with its segments
• Country-wise Blood Glucose Monitoring Devices market analysis
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

Country covered in the report:

• United States
• Canada
• Mexico

By Product

• Self-monitoring Devices
• Continuous Blood Glucose Monitoring Devices

By End User

• Hospitals
• Home Care
• Diagnostic Centers

By Indication

• Diabetes
• Pregnancy
• Cardiovascular Disorders & Hypertension
• Cancer
• Respiratory Diseases
• Movement Disorders
• Hearing Disorders
• Wound Care
• Other Indications (sleep disorders, kidney disorders, neurovascular diseases, and HIV)

The approach of the report:

This report consists of a combined approach of primary and secondary research. Initially, secondary research was used to get an understanding of the market and list the companies that are present in it. The secondary research consists of third-party sources such as press releases, annual reports of companies, and government-generated reports and databases. After gathering the data from secondary sources, primary research was conducted by conducting telephone interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this; we have started making primary calls to consumers by equally segmenting them in regional aspects, tier aspects, age group, and gender. Once we have primary data with us, we can start verifying the details obtained from secondary sources.

Intended audience

This report can be useful to industry consultants, manufacturers, suppliers, associations, and organisations related to the Blood Glucose Monitoring Devices industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing and presentations, it will also increase competitive knowledge about the industry.






***Please Note: It will take 48 hours (2 Business days) for delivery of the report upon order confirmation.

ページTOPに戻る

Table of Contents